Prokaryotic and eukaryotic protein synthesis inhibitor. Nucleoside that resembles the aminoacyl-adenylyl terminus of aminoacyl-tRNA and competes for binding to the "A site" of the large ribosomal subunit. Its incorporation into a growing polypeptide results in termination of chain elongation and release of the nascent polypeptidyl-puromycin. Used for selection of mammalian cell lines expressing a transfected pac gene (Streptomyces alboniger), whose product, puromycin acetyltransferase, inactivates the drug via acetylation. Induces DNA fragmentation in thymocytes and in human HL-60 leukemia cells. Like cycloheximide, puromycin is also used as a general protein synthesis inhibitor in numerous cellular assays.
Protein synthesis inhibitor. Inhibits translation by causing premature release of nascent polypeptide chains. Induces DNA fragmentation in thymocytes and in human HL-60 leukemia cells.
Puromycin, Dihydrochloride, CAS 58-58-2, is An aminonucleoside antibiotic that inhibits protein synthesis by blocking the translation step and causes premature release of nascent polypeptide chains.
25 mg in Glass bottle
100 mg in Plastic ampoule
Toxicity: Harmful (C)
Following reconstitution, sterilize by filtration through a 0.22 µm pore-size filter, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
Chow, S.C., et al. 1995. Exp. Cell Res. 216, 149.
Constam, D.B., et al. 1995. J. Biol. Chem.270, 26931.
Wirth, M., et al. 1994. J. Virol.68, 566.
Claeyssens, S., et al. 1993. FEBS Lett.315, 7.
Hechler, U., et al. 1993. Biochem. Biophys. Res. Commun.194, 1305.
Kaufman, S.H., et al. 1993. Cancer Res.53, 3976.
de la Luna, S. and Ortín, J. 1992. Methods Enzymol.216, 376.
Kalpaxis, D.L. and Drainas, D. 1992. Arch. Biochem. Biophys.300, 629.
Shipston, M.J. and Antoni, F.A. 1992. Biochem. Biophys. Res. Commun.189, 1382.
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany